Celsion Corporation (CLSN)

[kris_kade]

Just thinking loud...as a rough model, if you consider the stratification of patients between 3-5 cm & 5-7 cms lesions, the RFA efficacy is significantly poor on the later range (5-7) (refer to Celsion's presentation deck by Dr. Poon in september).

Ad with majority of patients (say ~65%) are in 3-5 range with remaining 35% on the >5 range, we have already a high odds of TDOX beating RFA up to 35% of the patients population. Another 15 to 20% from 3-5 range will easily total up to 50% or morein favor of TDOX as a whole. We just need to show a minimum of 33% to get TDOX approved.